---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-102828"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:58:55.653524+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical gets Nasdaq extension until Feb 23, 2026 to meet listing requirement

## Summary
- Nasdaq panel grants exception until Feb 23, 2026 to comply with $35M market value listing rule.
- Company cites recent equity raises, debt extinguishment, and FDA approval of final stage of Acclaim cochlear implant trial.
- Over 28 million shares outstanding; trading volume increased since trial expansion announcement.
- Company must promptly notify Nasdaq of any events affecting compliance during the exception period.

## SEC filing metadata
- accession: 0001213900-25-102828
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390025102828/0001213900-25-102828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390025102828/ea0262700-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-102828
- JSON: https://secwatch.observer/filing/0001213900-25-102828.json
- Plain text: https://secwatch.observer/filing/0001213900-25-102828.txt

## Source-grounded claims
- claim_id: b84e1e5fe68aea91edb1925af029fe58f7f0e8ab
  claim: Envoy Medical, Inc. received a nasdaq extension granted notice regarding market value (rules 5550(b)(2)).
  evidence_excerpt: October 23, 2025, the Nasdaq Hearings Panel (the “Panel”) notified Envoy Medical, Inc. (the “Company) that it has granted the Company’s request for an exception to demonstrate compliance with the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) for continued listing through February 23, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840877/000121390025102828/0001213900-25-102828-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.